Literature DB >> 10913301

Structural determinants for activity of glucagon-like peptide-2.

M P DaCambra1, B Yusta, M Sumner-Smith, A Crivici, D J Drucker, P L Brubaker.   

Abstract

Glucagon-like peptide-2 (GLP-2) is a 33 amino acid gastrointestinal hormone that regulates epithelial growth in the intestine. Dipeptidylpeptidase IV cleaves GLP-2 at the position 2 alanine, resulting in the inactivation of peptide activity. To understand the structural basis for GLP-2 action, we studied receptor binding and activation for 56 GLP-2 analogues with either position 2 substitutions or alanine replacements along the length of the peptide. The majority of position 2 substitutions exhibited normal to enhanced GLP-2 receptor (GLP-2R) binding; in contrast, position 2 substitutions were less well tolerated in studies of receptor activation as only Gly, Ile, Pro, alpha-aminobutyric acid, D-Ala, or nor-Val substitutions exhibited enhanced GLP-2R activation. In contrast, alanine replacement at positions 5,6,17, 20, 22, 23, 25, 26, 30, and 31 led to diminished GLP-2R binding. Position 2 substitutions containing Asp, Leu, Lys, Met, Phe, Trp, and Tyr, and Ala substitutions at positions 12 and 21 exhibited normal to enhanced GLP-2R binding but greater than 75% reduction in receptor activation. D-Ala(2), Pro(2) and Gly(2), Ala(16) exhibited significantly lower EC(50)s for receptor activation than the parent peptide (p < 0.01-0.001). Circular dichroism analysis indicated that the enhanced activity of these GLP-2 analogues was independent of the alpha-helical content of the peptide. These results indicate that single amino acid substitutions within GLP-2 can confer structural changes to the ligand-receptor interface, allowing the identification of residues important for GLP-2R binding and receptor activation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913301     DOI: 10.1021/bi000497p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

Review 1.  Gut adaptation and the glucagon-like peptides.

Authors:  D J Drucker
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

2.  Ligand binding pocket formed by evolutionarily conserved residues in the glucagon-like peptide-1 (GLP-1) receptor core domain.

Authors:  Mi Jin Moon; Yoo-Na Lee; Sumi Park; Arfaxad Reyes-Alcaraz; Jong-Ik Hwang; Robert Peter Millar; Han Choe; Jae Young Seong
Journal:  J Biol Chem       Date:  2015-01-05       Impact factor: 5.157

3.  Application of fourier transform and proteochemometrics principles to protein engineering.

Authors:  Frédéric Cadet; Nicolas Fontaine; Iyanar Vetrivel; Matthieu Ng Fuk Chong; Olivier Savriama; Xavier Cadet; Philippe Charton
Journal:  BMC Bioinformatics       Date:  2018-10-16       Impact factor: 3.169

4.  Novel agonist and antagonist radioligands for the GLP-2 receptor. Useful tools for studies of basic GLP-2 receptor pharmacology.

Authors:  Sarina Gadgaard; Wijnand J C van der Velden; Sine P Schiellerup; Jenna Elizabeth Hunt; Maria B N Gabe; Johanne Agerlin Windeløv; Geke Aline Boer; Hannelouise Kissow; Cathrine Ørskov; Jens J Holst; Bolette Hartmann; Mette M Rosenkilde
Journal:  Br J Pharmacol       Date:  2022-01-11       Impact factor: 9.473

5.  Mutational Landscape of the Proglucagon-Derived Peptides.

Authors:  Peter Lindquist; Jakob S Madsen; Hans Bräuner-Osborne; Mette M Rosenkilde; Alexander S Hauser
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-17       Impact factor: 5.555

6.  Novel Descriptors and Digital Signal Processing- Based Method for Protein Sequence Activity Relationship Study.

Authors:  Nicolas T Fontaine; Xavier F Cadet; Iyanar Vetrivel
Journal:  Int J Mol Sci       Date:  2019-11-11       Impact factor: 5.923

7.  GLP-2 Is Locally Produced From Human Islets and Balances Inflammation Through an Inter-Islet-Immune Cell Crosstalk.

Authors:  Wei He; Osmond D Rebello; Antonia Henne; Fabian Nikolka; Thomas Klein; Kathrin Maedler
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-05       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.